A Single-arm, Open-label, Dose-finding Clinical Study of TCR-T Cells in Patients With HLA-A2-expressing and NY-ESO-1-positive Recurrent or Metastatic Solid Tumors

Fujian Cancer Hospital0 sites30 target enrollmentStarted: December 2022Last updated: December 13, 2022

Conditions

Interventions

Drugs

Trial Snapshot

Phase: Early Phase 1
Status: Not yet recruiting
Sponsor: Fujian Cancer Hospital
Enrollment: 30
Primary Endpoint: Dose Limiting Toxicity

Study Overview Study Design Eligibility Criteria Arms & Interventions Outcomes Investigators Records & Identifiers Similar Trials

Study Overview

Brief Summary

New York Esophageal Squamous Cell Carcinoma 1 (NY-ESO-1) is a Cancer-Testis Antigen (CTA) which is expressed in various tumors. After selected the high affinity TCR gene to NY-ESO-1, the researchers insert genes into the cell that expressing a kind of protein that targeting NY-ESO-1. Then the engineered cells are re-infused in the patients with tumors for curing the tumor patient or prolonging life.

Detailed Description

This is a single-center, open-label, Phase I clinical study of TCR-T cells for the treatment of the recurrent/metastatic solid tumors patients who had failed standard therapy.

TCR-T cells are expanded from peripheral blood, and after ex vivo modification, and extensive expansion, are reinfused to patients after non-myeloablative lymphocyte-depleting preparative regimen.

The primary purpose of this study is to evaluate the safety and tolerability of TCR-T cells in patients with recurrent/metastatic solid tumors.

The second purpose of this study is to preliminarily explore the effectiveness of TCR-T cells in patients with recurrent/metastatic solid tumors.

Eligibility:

Study Design

Study Type: Interventional
Allocation: Na
Intervention Model: Sequential
Primary Purpose: Treatment
Masking: None

Eligibility Criteria

Ages: 18 Years to 70 Years (Adult, Older Adult)
Sex: All
Accepts Healthy Volunteers: No

Inclusion Criteria

•Have the willingness to communicate with investigator, be able to understand and follow the trail requirements, and voluntarily to participate in the trail;
•18 ~70 years old (gender is not limited;)
•The expected survival period is at least 3 months;
•ECOG score of 0-1;
•Patients with recurrent or metastatic solid tumors confirmed by histopathology;
•Subjects who failed standard treatment in the past or have no standard treatment currently tor who are judged by the investigator to be unsuitable for current standard treatment for other reasons, and the objective imaging assessment is disease progression;
•According to RECIST 1.1 standard, there is at least one measurable target lesion for efficacy evaluation;
•NY-ESO-1 positive;
•HLA type is HLA-A2 (except HLA-A*0203);

Exclusion Criteria

•Female subjects who are pregnant or breastfeeding, or have a positive blood pregnancy test at baseline;
•Subjects who have had severe allergic reactions to any drug or its components in this trial in the past;
•Subjects who have received any investigational drug within 28 days before the infusion of TIL cells, or participated in another clinical study at the same time;
•Subjects who have other known history of malignant tumors in the past 5 years, except for localized tumors that have been cured, including in situ cervical carcinoma, basal cell carcinoma of the skin, and in situ prostate carcinoma;
•Patients who have received adoptive cell therapy in the past;
•According to the judgment of the investigator, the condition of the subject is not suitable for this trial.